Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Multiple Myeloma | Research

Expression of NEAT1 can be used as a predictor for Dex resistance in multiple myeloma patients

Authors: Yuyue Ren, Yijun Liu, Wanting He, Weiwei Zhao, Jiaqi Pan, Haiyan Gao, Yuying Li, Ying Zhang, Wei Wang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Objective

Multiple myeloma is a heterogeneous disorder and the intratumor genetic heterogeneity contributes to emergency of drug resistance. Dexamethasone has been used clinically for decades for MM. Nevertheless, their use is severely hampered by the risk of developing side effects and the occurrence of Dex resistance. LncRNA NEAT1 plays a oncogenic role and participates in drug resistance in many solid tumors. Therefore, we investigated a potential usefulness of this molecular as a biomarker for diagnosis of MM and possible correlations of NEAT1 expression with drug resistance and prognosis.

Methods

Bone marrow and peripheral blood mononuclear cells samples were collected from 60 newly diagnosed MM patients. The expression of NEAT1expression level were detected by quantitative real-time PCR analyses. The relationship about the expression levels of lncRNA with other clinical and cytogenetic features was analyzed. In addition, we measured to analysis the correlation between the expression of NEAT1 and Dex resistance in MM patients.

Results

It was found that the expression of NEAT1 is significantly higher in multiple myeloma patients compared to controls and does not change with other clinical features and cytogenetic features. We further discovered that overexpression of NEAT1 was associated with Dex resistance and a poor prognosis in MM patients.

Conclusion

LncRNA NEAT1 has a significant value that might act as a promoting factor in the development of MM and may be severed as a diagnostic factor in MM. NEAT1 invovled in Dex resistance, which provide a new interpretation during the chemotherapy for MM.
Appendix
Available only for authorised users
Literature
1.
Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175–87.CrossRefPubMed
2.
Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31(9):1915–21.CrossRefPubMedPubMedCentral
3.
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat reviews Disease primers. 2017;3:17046.CrossRefPubMed
4.
Allegra A, Fazio E, Franco D, Nicolo M, Trusso S, Neri F, et al. Low-energy laser irradiation promotes cellular damage in glucocorticoid-resistant multiple myeloma cells. Leuk Lymphoma. 2015;56(5):1514–6.CrossRefPubMed
5.
Dong H, Carlton ME, Lerner A, Epstein PM. Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol. 2015;6:230.CrossRefPubMedPubMedCentral
6.
Avet-Loiseau H, Magrangeas F, Moreau P, Attal M, Facon T, Anderson K, et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol. 2011;29:1893–7.CrossRef
7.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.CrossRefPubMed
8.
Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. The emerging roles of long non-coding RNA in Cancer. Cancer Sci. 2018.
9.
Renganathan A, Felley-Bosco E. Long noncoding RNAs in Cancer and therapeutic potential. Adv Exp Med Biol. 2017;1008:199–222.CrossRefPubMed
10.
Tano K, Onoguchi-Mizutani R, Yeasmin F, Uchiumi F, Suzuki Y, Yada T, et al. Identification of minimal p53 promoter region regulated by MALAT1 in human lung adenocarcinoma cells. Front Genet. 2017;8:208.CrossRefPubMed
11.
Wu W, Chen F, Cui X, Yang L, Chen J, Zhao J et al. LncRNA NKILA suppresses TGF-beta-induced epithelial-mesenchymal transition by blocking NF-kappaB signaling in breast Cancer. Int J Cancer. 2018.
12.
Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, et al. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett. 2015;359(1):75–86.CrossRefPubMed
13.
Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, Huang Z et al. LncRNA HOTAIR is a prognostic biomarker for the Proliferation and Chemoresistance of Colorectal Cancer via MiR-203a-3p-Mediated Wnt/ss-Catenin signaling pathway. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2018;46(3):1275–85.
14.
Chang ZW, Jia YX, Zhang WJ, Song LJ, Gao M, Li MJ, et al. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. Journal of experimental & clinical cancer research. CR. 2018;37(1):56.PubMedPubMedCentral
15.
Meng H, Han L, Hong C, Ding J, Huang Q. Aberrant lncRNA expression in multiple myeloma. Oncol Res. 2017.
16.
Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H, et al. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J experimental Clin cancer research: CR. 2015;34:102.CrossRefPubMedCentral
17.
Qureshi IA, Mattick JS, Mehler MF. Long non-coding RNAs in nervous system function and disease. Brain Res. 2010;1338:20–35.CrossRefPubMed
18.
Cho SF, Chang YC, Chang CS, Lin SF, Liu YC, Hsiao HH, Chang JG, Liu TC. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer 2014 Nov 4;14:809.
19.
Fang J, Qiao F, Tu J, Xu J, Ding F, Liu Y, et al. High expression of long non-coding RNA NEAT1 indicates poor prognosis of human cancer. Oncotarget. 2017;8(28):45918–27.CrossRefPubMedPubMedCentral
20.
Chen X, Kong J, Ma Z, Gao S, Feng X. Up regulation of the long non-coding RNA NEAT1 promotes esophageal squamous cell carcinoma cell progression and correlates with poor prognosis. Am J cancer Res. 2015;5(9):2808–15.CrossRefPubMedPubMedCentral
21.
Peng W, Wang Z, Fan H. LncRNA NEAT1 impacts cell proliferation and apoptosis of Colorectal Cancer via regulation of akt signaling. Pathol Oncol research: POR. 2017;23(3):651–6.CrossRefPubMed
22.
Zhang J, Li Y, Dong M, Wu D. Long non-coding RNA NEAT1 regulates E2F3 expression by competitively binding to miR-377 in non-small cell lung cancer. Oncol Lett. 2017;14(4):4983–8.CrossRefPubMedPubMedCentral
23.
Liu Y, Wang Y, Fu X, Lu Z. Long non-coding RNA NEAT1 promoted ovarian cancer cells’ metastasis via regulating of miR-382-3p/ROCK1 axial. Cancer Sci. 2018.
24.
Xiong W, Huang C, Deng H, Jian C, Zen C, Ye K, et al. Oncogenic non-coding RNA NEAT1 promotes the prostate cancer cell growth through the SRC3/IGF1R/AKT pathway. Int J Biochem Cell Biol. 2018;94:125–32.CrossRefPubMed
25.
Zeng C, Xu Y, Xu L, Yu X, Cheng J, Yang L, et al. Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer. 2014;14:693.CrossRefPubMedPubMedCentral
26.
Zhang J, Zhao B, Chen X, Wang Z, Xu H, Huang B. Silence of long noncoding RNA NEAT1 inhibits malignant Biological Behaviors and Chemotherapy Resistance in Gastric Cancer. Pathol Oncol research: POR. 2018;24(1):109–13.CrossRef
27.
Jiang P, Chen A, Wu X, Zhou M, Ul Haq I, Mariyam Z, Feng Q. NEAT1 acts as an inducer of cancer stem cell-like phenotypes in NSCLC by inhibiting EGCG-upregulated CTR1. J Cell Physiol. 2018 Jun;233(6):4852–63.
28.
Li X, Wang S, Li Z, Long X, Guo Z, Zhang G et al. Retracted: NEAT1 induces epithelial-mesenchymal transition and 5-FU resistance through the miR-129/ZEB2 axis in breast cancer. FEBS Lett. 2016.
29.
Gao C, Zhang J, Wang Q, Ren C. Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia. Oncol Lett. 2016;12(2):1051–7.CrossRefPubMedPubMedCentral
30.
Huang S, Qian K, Zhu Y, Huang Z, Luo Q, Qing C. Diagnostic value of the lncRNA NEAT1 in Peripheral Blood mononuclear cells of patients with Sepsis. Dis Markers. 2017;2017:7962836.CrossRefPubMedPubMedCentral
31.
Ren Y, Li X, Wang W, He W, Wang J, Wang Y. Expression of Peripheral Blood miRNA-720 and miRNA-1246 can be used as a predictor for Outcome in multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):415–23.
32.
Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002;9(1):6–19.CrossRefPubMed
33.
Vrana JA, Cleaveland ES, Eastman A, Craig RW. Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. Apoptosis: an international journal on programmed cell death. 2006;11(8):1275–88.CrossRefPubMed
34.
35.
Ghosh N, Tucker N, Zahurak M, Wozney J, Borrello I, Huff CA. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol. 2014;89(8):E116–20.CrossRefPubMedPubMedCentral
36.
37.
Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 2013;13(Suppl 1):125–37.CrossRef
38.
Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, et al. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. Eur J Haematol. 2017;99(3):223–33.CrossRefPubMed
39.
Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin cancer research: official J Am Association Cancer Res. 2013;19(13):3337–44.CrossRef
40.
41.
Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M et al. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia. 2018.
42.
Vandevyver S, Dejager L, Libert C. Comprehensive overview of the structure and regulation of the glucocorticoid receptor. Endocr Rev. 2014;35(4):671–93.CrossRefPubMed
43.
Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42–54.CrossRefPubMed
44.
Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99(6):1885–93.CrossRefPubMed
45.
Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004;104(9):2886–92.CrossRefPubMed
46.
Wu Y, Wang H. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 2018;32(1).
Metadata
Title
Expression of NEAT1 can be used as a predictor for Dex resistance in multiple myeloma patients
Authors
Yuyue Ren
Yijun Liu
Wanting He
Weiwei Zhao
Jiaqi Pan
Haiyan Gao
Yuying Li
Ying Zhang
Wei Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11084-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer

Research

Expression signature and prognostic value of CREC gene family in human colorectal cancer

Research

YTHDF3as a prognostic predictive biomarker of thyroid cancer and its correlation with immune infiltration

Research

Symptom management care pathway adaptation process and specific adaptation decisions

Research

How frail is frail in oncology studies? A scoping review

Research

Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits